TCT-174 EPIC Nitinol Stent Treatment of Iliac Artery Lesions: 12-Month Outcomes in the ORION Study  by Clair, Daniel et al.
TCT-173
Bare-nitinol stent versus paclitaxel-coated balloon for femoro-popliteal
revascularization. An adjusted indirect comparison meta-analysis of
randomized trials
Salvatore Cassese1, Robert Byrne1, Ilka Ott1, Tareq Ibrahim2, Tomohisa Tada1,
Lamin King1, Adnan Kastrati1, Massimiliano Fusaro1
1Deutsches Herzzentrum Munich, Munich, Germany, 21. Kilinikum Rechts der Isar,
Munich, Germany
Background: In femoro-popliteal artery (FPA) disease, Bare-Nitinol Stent (BNS) and
Paclitaxel-coated balloon (PCB) improved outcomes as compared to Uncoated-Balloon
(UCB) angioplasty. Nevertheless, the relative efficacy of BNS vs. PCB remains unknown,
due to the lack of head-to-head comparisons. We performed an adjusted indirect
comparison meta-analysis of randomized trials to evaluate outcomes of BNS versus PCB
in FPA disease.
Methods: A systematic literature search (PubMed, EMBASE, the Cochrane Central
Register of Controlled Trials, scientific session abstracts and relevant websites) through
December 2011 was performed. Selected search words were: superficial-femoral artery,
popliteal artery, angioplasty, self-expanding stent, nitinol-stent, bare-stent, drug-eluting
balloon, paclitaxel-coated balloon, and randomized trial. Inclusion criteria were: random-
ized trial design, intention to treat analysis, 6-month follow-up (FU). Exclusion criteria
were: other arterial segments treated than FPA, comparison other than BNS/PCB vs.
UCB, irretrievable, duplicated or incomplete data. Odds ratio (OR [95% confidence
intervals]) and z scores (z), with corresponding p values, were used as summary statistics.
Main outcomes were target lesion revascularization (TLR), binary restenosis and all cause
mortality.
Results: We identified 8 eligible trials, enrolling a total of 1,008 patients randomized to
BNS/PCB or UCB angioplasty (BNS n 342, PCB n 186, UCB n 480). Median FU
was 11.5 months. Angioplasty with BNS was found inferior to PCB with respect to TLR
(OR 2.60 [1.27–5.32], z 2.63, p 0.008), with a trend toward higher binary restenosis
(OR 2.03 [0.99–4.18], z 1.93, p 0.052). No significance in mortality was evident
among study groups (OR 1.79 [0.37–8.55], z 0.73, p 0.46; BNS vs. PCB
comparison).
Conclusions: In diseases of femoro-popliteal artery, PCB offers superior freedom from
repeat revascularization as compared to BNS. Both revascularization strategies appeared
safe. Adequately powered, randomized, head-to-head comparisons are needed.
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Background: ORION is a prospective, multicenter, single-arm, long-term safety and
efficacy study of the Epic™ vascular self-expanding stent for the treatment of iliac artery
lesions.
Methods: Eligible patients had chronic, symptomatic iliac disease and received2 stents
for de novo/restenotic lesions in the common or external iliac arteries. Lesions were 13
cm in length with diameter stenosis 50%. Clinical, functional, hemodynamic, and
duplex ultrasound follow-up was performed at 30 days and 9 and 12 months. Key
endpoints evaluated at one year include primary, primary-assisted, and secondary patency,
target lesion revascularization (TLR), stent thrombosis, amputation, assessment of the
walking impairment questionnaire and ankle-brachial index (ABI). All deaths, revascu-
larization, myocardial infarctions, amputations, and stent thromboses were adjudicated by
an independent clinical events committee (CEC).
Results: A total of 125 patients were enrolled in the study. Through 12 months, primary
patency, primary-assisted patency, and secondary patency was achieved in 94.4%
(119/126), 96.0% (121/126), and 97.6% (122/125) of treated lesions and 95.4% of patients
remained free from TLR. Improvement in ABI by 0.1 was seen in 63.6% (84/132) of
treated limbs. Three patients had stent thrombosis through 30 days and 2 patients died
through 12 months. There were no amputations performed. Across the patient population,
statistically significant improvements from baseline in walking distance (P 0.0001),
walking speed (P 0.0001), and stair climbing (P 0.0001) were reported through 12
months.
Conclusions: The Epic stent is a safe and effective tool for the treatment of iliac artery
lesions. The reported results demonstrate marked improvements in clinical, hemody-
namic, and functional outcomes.
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Background: Angioplasty for patients with critical limb ischemia (CLI) is effective to
avoid major amputation. Although optimal antiplatelet therapy to improve the long term
outcome following the angioplasty remains to be elucidated.
Methods: Between March 2004 and October 2010, 1057 limbs from 884 patients with
CLI due to isolated infrapopliteal lesions were retrospectively analyzed. In hospital death
cases (n22) and patients who did not taking aspirin (n216) were excluded. Primary
endpoint is freedom-from MALE (major adverse limb event defined as major amputation
or any reintervention) and assessed out to 2 years by the KaplaneMeier methods.
Results: Study population were divide into 4 groups due to antiplatelet status. Baseline
characteristics was not different except for coronary artery disease. Freedom-from MALE
at 2 years were 54% in aspirin and cilostazol (AC) group, 44% in triple antiplatelet
therapy (T) group, 36% in aspirin alone (A) group and 35% in aspirin and thienopyridine
(AT) group, respectively (p0.0006). Cumulative incidence of major amputation was
12.8% in AC, 18.1% in AT, 22.4% in T and 35% in A group, respectively (p0.0003).
Conclusions: The combination of aspirin and cilostazol associated with better outcome
for CLI due to isolated infrapopliteal lesions. Further studies are warranted to investigate
which antiplatelet regimen could be a optimal option in CLI patients.
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Background: Infrapopliteal (IP) chronic total occlusions (CTOs) are common in
diabetics and patients presenting with critical limb ischemia (CLI). As endovascular
procedures for CLI evolve, IP CTO recanalization is being attempted with increasing
frequency. We analyzed the clinical and procedural outcomes following endovascular
intervention for IP CTO at our institution.
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